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Abstract: The preparation and biological evaluation of a novel series of dimeric epothilone A 
derivatives (1 - 6) are described. Two types of diacyl spacers were introduced to establish the 
various dimeric epothilone A constructs. The effect of these compounds on tubulin polymerization 
and their cytotoxicity against four different cancer cell lines are reported. Several of the newly 
synthesized compounds inhibit endothelial cell differentiation and endothelial cell migration that 
are key steps of the angiogenic process. 
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1. Introduction 
 
Substances that are able to interfere with the tubulin-microtubule system, either through inhibition 
of tubulin polymerization or through microtubule stabilization, are important anticancer agents. 
Prominent examples are the vinca alkaloids (which act as tubulin polymerization inhibitors) or the 
diterpenoid alkaloid taxol and its semi-synthetic derivative docetaxel (which are microtubule 
stabilizers), all of which are indispensable components of modern cancer chemotherapy regimens.1 
The most recent addition to the clinical arsenal of tubulin inhibitors is the lactam analog of the 
bacterial natural product epothilone B2 (Epo B, Figure 1), which has been approved for clinical use 
by the US FDA in late 2007 under the trade name Ixempra® (generic name: ixabepilone).3 In 
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addition to their growth-inhibitory and apoptosis-inducing activity, some tubulin inhibitors have 
recently been shown to target the vascular system of tumors,4 thereby causing vasculature recession 
(induction of apoptosis by a classical anti-angiogenic mechanism) or vasculature “normalization”.5 
Vasculature normalization facilitates and enhances tumor cell penetration by anticancer drugs, thus 
offering the opportunity for extensive tumor kill by appropriate drug combinations. As a 
consequence, the identification of new tubulin modulators6 remains an important challenge in 
anticancer drug discovery and the use of well known tubulin-interacting agents as scaffolds is a 
represents reasonable approach towards this goal. In this context, we have been intrigued by a 
dimeric epothilone analog (Epo-Dim, Figure 1) that has been reported by Nicolaou and co-workers7 
several years ago as an undesired side product in the course of the target-oriented synthesis of a 
series of side chain-modified epothilones. Although no specific data were provided for this analog,7 
the compound is stated to exhibit remarkable tubulin-polymerizing and antiproliferative activity. 
Building on these earlier findings we have now synthesized a set of a epothilone dimers that are 
more readily accessible than Epo-Dim and we have investigated the in vitro biological properties of 
these new epothilone derivatives (Scheme 1).8  
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Figure 1: Epothilones A and B. Structure of the dimeric epothilone analog Epo-Dim described by K.C. Nicolaou (Ref. 
7).  
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2. Results and Discussion 
2.1 Chemistry 
The presence of two hydroxyl groups in the epothilone macrocycle offered an opportunity for the 
direct introduction of a spacer moiety between two epothilone monomers. Assuming the OH-group 
on C3 to be sterically more hindered, we felt that the acylation of C7-OH should be feasible with 
reasonable selectivity and thus provide C7 linked dimers as the major prodcuts of the reaction of 
Epo A with activated dicarboxylic acids.9 While being aware of the potential in vivo lability of the 
ester function our initial objective was to prepare a number of prototypical dimers in the simplest 
way possible and to evaluate these compounds in tubulin polymerisation assays. Thus reaction of 
Epo A with six different dicarboxylic acids in the presence of DCC and DMAP (Scheme 1) gave 
the corresponding products (1 – 6) with excellent regioselectivity. The latter compensated at least 
partially, for the low to moderate yields obtained in the esterification reactions (25 – 40 %). 
Esterification of the C7-OH group in the derivatives isolated (rather than C3-OH) was demonstrated 
by NMR spectroscopy. The spectra of 1 - 6 exhibit a single set of signals for the epothilone unit 
with chemical shifts that are similar to those in the spectrum of Epo A, except for the signal for H-
7, which is down-shifted to δ 5.37 - 5.44  (Epo A δ 3.80). All compounds appeared sufficiently 
stable chemically under the conditions of the biological experiments.  
7
7
3
O
OH
OH
O
S
N
OO
O
X
O
O
X
O
O H
OH
S
N
O O
n
nHO
X
O
OH
O
X
DCC, DMPA
     6-8 h
n n
Epo A
1 - 6
 
 
 
 4 
Compound 1 2 3 4 5 6 
n 1 2 3 1 2 3 
X S S S CH2 CH2 CH2 
Scheme 1: General preparation of derivatives 1 – 6.  
   
2.2 Influence on Tubulin Polymerization  
In order to assess the interaction of compounds 1 – 6 with the tubulin/microtubule system, they 
were tested in an in vitro tubulin polymerization assay at fixed concentrations of 5 and 10 µM. As 
illustrated by the data in Table 1, Epo A at these concentrations induces almost complete assembly 
of soluble tubulin into microtubule polymers. In contrast, no physically meaningful tubulin 
assembly could be detected for any of the dimeric analogs 1 – 6 under the same experimental 
conditions. While it cannot be excluded that tubulin polymerization might be detectable under a 
different set of experimental conditions, it is clear from the data in Table 1 that dimers 1 – 6 are 
substantially less potent inducers of tubulin polymerization than Epo A in vitro (if any).  
Given the chemical stability of all the dimeric compounds 1 - 6 under the conditions of a cell 
culture assay and in light of a noticeably improved solubility (compared with Epo A) the 
antiproliferative activity of these compounds was evaluated against a series of cancer cells. 
 
Compound % Tubulin Polym. [a]  A-549 MCF-7 HT-1080 βD10[b] BAE Tubes Migration 
 (10 μM) (5 μM) IC50[c] MIC[d] 
Epo A 99.8 ± 0.4 92.2 ± 2.3 2.6+ 0.23 2.5+ 0.29 1.3+ 0.5 70 0.7+ 0.4 5 5 
1 1 ± 0.5 0.3 ± 0.4 319+ 21 357+ 44 290+ 98 1000 29+ 3 100 50 
2 0.2 ± 0.4 0 ± 0.3 367+ 18 379+ 20 43+ 18 3.3 111+ 73 50 100 
3 0.2 ± 0.6 0.5 ± 0.7 383+ 30 432+ 17 71+ 15 2000 133+ 30 100 100* 
4 0.7 ± 0.4 0.2 ± 0.4 405+ 27 412+ 18 69+ 22 70500 40+ 10 100 100 
5 0.3 ± 0.5 0.7 ± 0.5 316+ 17 321+ 28 17+ 13 2500 20+ 13 100 100 
6 0.6 ± 0.5 0.1 ± 0.7 956+ 43 1033+ 39 13+ 3 5020 39+ 8 50 100* 
Table 1. Biological evaluation of compounds 1 – 6. [a] Polymerization was monitored at a fixed compound 
concentratin of 5 or 10 µM by following the increase in absorption at 340 nm; [b] Cells from lung tumors of double c-
myc and c-raf transgenic mice; [c] Compound concentration, in nM, that causes 50% inhibition of the control cell 
growth, data are means ±S.D. of at least three independent experiments with triplicate samples each; [d] Minimal 
inhibitory concentration of compounds 1-6 (MIC) on BAE (bovine aortic endothelial) cell differentiation (Tube 
formation) or migration. The different assay was carried out in the presence of different concentrations of Epo A and 
dimers 1-6 as described in Experimental Section. Migration assay was carried out in the presence of different 
concentrations of epothilone A and related compounds as described in Experimental Section. 
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2.3 Cytotoxicity 
The anticancer activities of the new compounds were examined in three different human cancer cell 
lines, namely A549 (lung cancer), MCF7 (breast cancer), and HT1080 (fibrosarcoma) and in one 
transformed mouse cell line that is derived from lung tumors of double c-myc and c-raf transgenic 
mice (βD10)10 (Table 1). With one exception all compounds investigated were found to be less 
active than the parent compound Epo A, thus reflecting the reduced ability of the dimeric analogs to 
induce tubulin polymerization in vitro. It remains to be determined, whether the observed cellular 
activity is in fact associated with the dimers as such or whether it may be a consequence of (partial) 
enzyme-mediated ester hydrolysis (either in the cell culture medium or inside the cells) and the 
ensuing release of free Epo A. As an exception, the stem cell line βD10 appeared to be more 
sensitive to 2 than to Epo A. The reason for this behavior are unclear at this point. 
2.4 Anti-angiogenic activity  
Angiogenesis involves local proliferation of endothelial cells.11 Therefore, we also investigated the 
ability of Epo A and dimers 1-6 to inhibit the growth of endothelial cells. As illustrated by the IC50 
values shown in Table 1, the dimeric epothilone analogs inhibit endothelial cell growth at 
submicromolar concentrations. But they are clearly less potent than the parent compound Epo A. 
Comparison of these results with those obtained with tumor cells (previous paragraph) demonstrates 
that the inhibitory effect is not endothelial cell specific in the case of compounds 2-6 and Epo A. 
The data suggest, however, that compound 1 could present a higher cell growth inhibitory activity 
for endothelial cells when compared to that on tumor cells. 
The final event during angiogenesis is the organisation of endothelial cells into a three-dimensional 
network of tubes. In vitro, endothelial cells plated on Matrigel align themselves forming cords, 
already evident a few hours after plating. Figure 2b shows that 5 nM Epo A was able to completely 
inhibit the BAE cell alignment and cord formation. Dimerization of Epo A decreases the 
endothelial morphogenesis inhibitory activity. An inhibition of endothelial morphogenesis on 
Matrigel was obtained with 50 nM compound 6, or with 100 nM compounds 1-5 (Figure 2c-h). 
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Angiogenesis involves the acquisition by endothelial cells of the capability to migrate through the 
extracellular matrix, degrade the basement membrane and, in general, to remodel the extracellular 
matrix. Our results, presented in Figure 3a, show that 5 nM Epo A produced a significant inhibition 
of the migratory capability of BAE cells. As shown in Figure 3b-h, a significant effect on BAE cells 
migration was observed in the presence of compound 1 (50 nM) or compounds 2-6 (100 nM). 
 
Figure 2. Effects of Epo A and dimeric derivatives on endothelial cells: a) control; b) Epo A, 5 nM; c) 1, 100 nM; d) 2 
100 nM; e) 3, 100 nM; f) 4, 100 nM; g) 5, 100 nM; h) 6, 50 nM. 
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Figure 3. Effect of Epo A and dimeric derivatives on endothelial cell migration. a) control; b) Epo A, 5 nM; c) 1, 50 
nM; d) 2, 100 nM; e) 3, 100 nM; f) 4, 100 nM; g) 5, 100 nM; h) 6, 100 nM. 
 
 
3. Conclusions 
 
Our results indicate that several Epo A related dimeric compounds inhibit endothelial cell 
differentiation and endothelial cell migration, which are key steps of the angiogenic process, at non-
toxic concentrations. The discovery that these compounds interfere with several functions of 
activated endothelial cells suggests that they could be of interest for the development of new agents 
for the treatment of angiogenesis-related diseases. 
4. Experimental Section 
General: Thin-layer chromatography (TLC) was performed on Merck precoated 60F254 plates. 
Reactions were  monitored by TLC on silica gel, with detection by UV light (254 nm) or by 
charring with sulfuric acid. Flash chromatography was performed using Silica gel (240–400 mesh, 
Merck). 1H NMR spectra were recorded with Brucker 200, 300 and 400 MHz spectrometers using 
chloroform-d (CDCl3) and methanol-d4 (CD3OD). Chemical shifts are reported in parts per million 
(δ) downfield from tetramethylsilane (TMS) as internal standard. EI mass spectra were recorded at 
an ionizing voltage of 6Kev on a VG 70-70 EQ. ESI mass spectra were recorded on FT-ICR 
APEXII  (Bruker Daltonics). All reactions were carried out in dry solvents. 
Cell culture media were purchased from Gibco (Grand Island, NY, USA) and Biowhittaker 
(Walkersville, MD, USA). Fetal bovine serum (FBS) was a product of Harlan-Seralab (Belton, 
U.K.). Matrigel was purchased from Becton Dickinson (Bedford, MA, USA). Supplements and other 
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chemicals not listed in this section were obtained from Sigma Chemicals Co. (St. Louis, Mo., USA). 
Plastics for cell culture were supplied by NUNC (Roskilde, Denmark). Epothilone A and related 
compounds (figure 1) were dissolved in dimethylsufoxide (DMSO) at a concentration of 10  mM and 
stored at –20ºC until use.  Bovine aortic endothelial (BAE) cells were obtained by collagenase 
disgestion and maintained in Dulbecco’s modified Eagle’s medium containing glucose (1g/L), 
glutamine (2mM), penicillin (50 IU/mL), streptomycin (50 µg/mL), and amphoterycin (1.25 µg/mL) 
(DMEM) supplemented with 10% FBS (DMEM/10%FBS). Human fibrosarcoma HT1080 cells were 
obtained from the ATCC and maintained in DMEM containing glucose (4.5 g/L), glutamine (2mM), 
penicillin (50 IU/mL), streptomycin (50 µg/mL), and amphoterycin (1.25 µg/mL) supplemented with 
10% FBS.   
 
General procedure for preparation of compounds 1 - 6: DMAP (0.05 mmol), epothilone (0.1 
mmol) and DCC (0.15 mmol) were added to a solution of diacid (0.05 mmol) in CH2Cl2 dry at 
room temperature. The mixture was stirred for 6-8 hours then concentrated under reduced pressure. 
The crude residue was purified by flash chromatography (silica gel, AcOEt/Hexane 3:2) to give the 
dimeric compounds. Yields: 25 – 40 %. 
 
Epothilone A: 1H NMR (400 MHz, CDCl3) δ 6.99 (1H, s), 6.61 (1H, s), 5.44 (1H, dd, J = 2.5, 8.7 
Hz), 4.21-4.19 (1H, m), 3.95 (1H, bs), 3.80 (1H, t, J = 4.3 Hz), 3.50 (1H, br s), 3.27-3.21 (1H, m), 
3.06-3.02 (1H, m), 2.94-2.90 (1H, m), 2.71 (3H, s), 2.66 (1H, br s), 2.55 (1H, dd, J = 14.5, 10.5 
Hz), 2.42 (1H, dd, J = 14.5, 3.2 Hz), 2.17-2.12 (1H, m), 2.11 (3H, s), 1.93-1.85 (1H, td, J = 15.1, 
8.4 Hz), 1.78-1.72 (2H, m), 1.57-1.41 (5H, m), 1.38 (3H, s), 1.18 (3H, d, J = 6.8 Hz), 1.11 (3H, s), 
1.01 (3H, d, J = 7.0 Hz); 13C NMR (100.6 MHz, CDCl3) δ 218.8 (1C), 171.1 (1C), 165.8 (1C), 
152.4 (1C), 138.2 (1C), 120.4 (1C), 116.8 (1C), 77.2 (1C), 75.2 (1C), 73.8 (1C), 58.0 (1C), 55.2 
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(1C), 44.0 (1C), 39.6 (1C), 36.9 (1C), 32.2 (1C), 31.2 (1C), 27.8 (1C), 24.1 (1C), 22.2 (1C), 21.0 
(1C), 19.6 (1C), 17.7 (1C), 16.3 (1C), 14.6 (1C). 
 
1 : 1H NMR (400 MHz, CDCl3) δ 7.01 (2H, s), 6.67 (2H, s), 5.52 (2H, dd, J = 6.5, 2.1 Hz), 5.44 
(2H, dd, J = 1.7, 8.9 Hz), 4.17-4.12 (2H, m), 3.5-3.4 (2H, dd, J = 9.83, 6.99 Hz), 3.12-3.05 (2H, m), 
2.95-2.88 (2H, m), 2.73 (6H, s), 2.60-2.55 (4H, m), 2.15 (6H, s), 2.13-2.10 (2H, m), 2.00-1.98 (2H, 
m), 1.82-1.79 (2H, m), 1.66-1.55 (8H, m), 1.40 (8H, s), 1.30-1.26 (6H, s), 1.13 (6H, s), 1.10 (6H, d, 
J = 6.8 Hz), 0.96 (6H, d, J = 6.8 Hz); 13C NMR (100.6 MHz, CDCl3) δ 216.1 (2C), 170.3 (2C), 
168.7 (2C), 164.9 (2C), 152.1 (2C), 136.8 (2C), 119.8 (2C), 116.3 (2C), 80.2 (2C),  76.0 (2C), 73.9 
(2C), 57.3 (2C), 53.7 (2C), 52.3 (2C), 43.8 (2C), 38.4 (2C), 34.4 (2C), 30.8 (2C), 29.2 (4C), 26.2 
(2C), 24.1 (2C) , 22.2 (2C), 20.8 (2C), 18.9 (2C), 17.4 (2C), 16.6 (2C), 15.5 (2C); Anal. Calcd. for 
C56H80N2O14S4: C , 59.34; H, 7.11; N, 2.47. Found: C , 59.38; H, 7.15; N, 2.43 [α]D25 = -2.2 (c 0.85, 
CHCl3); HRESI positive MS: Anal. Calcd. for C56H80N2O14S4Na+, 1155.43846; found 1155.43862. 
 
2 : 1H NMR (400 MHz, CDCl3) δ 7.00 (2H, s), 6.64 (2H, s), 5.50 (2H, br. d, J = 4.7 Hz), 5.41 (2H, 
d, J = 9.1 Hz), 4.16-4.11 (2H, m), 3.44-3.36 (2H, m), 3.16-3.06 (2H, m), 2.98 (4H, t, J = 7.1 Hz), 
2.93-2.90 (2H, m), 2.80 (8H, t, J = 7.0 Hz), 2.72 (6H, s), 2.60-2.51 (4H, m), 2.13 (6H, s), 2.07-1.94 
(4H, m), 1.80-1.71 (2H, m), 1.68-1.53 (8H, m), 1.39 (6H, s), 1.40-1.35 (2H, m), 1.29-1.24 (2H, m), 
1.12 (6H, s), 1.09 (6H, d, J = 6.7 Hz), 0.95 (6H, d, J = 6.7 Hz). 13C NMR (100.6 MHz, CDCl3) δ 
217.2 (2C), 171.8 (2C), 171.1 (2C), 165.5 (2C), 152.8 (2C), 137.2 (2C), 120.7 (2C), 117.0 (2C), 
79.7 (2C), 76.7 (2C), 74.7 (2C), 58.0 (2C), 54.5 (2C), 53.0 (2C), 44.4 (2C), 39.0 (2C), 35.0 (2C), 
34.8 (2C),  34.0 (2C),  32.0 (2C),  29.9 (2C) 26.9 (2C), 24.7 (2C) , 22.9 (2C), 21.0 (2C), 19.7 (2C), 
18.2 (2C),  16.3 (2C), 16.2 (2C); Anal. Calcd. for C58H84N2O14S4: C, 59.97; H, 7.29; N, 2.41. 
Found: C, 59.99; H, 7.31; N, 2.43 [α]D25 = -2.96 (c  0.455, CHCl3); HRESI positive MS: Anal. 
Calcd. for C58H84N2O14S4Na+, 1183.46976; found 1183.46837. 
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3 : 1H NMR (400 MHz, CDCl3) δ 7.05 (2H, s), 6.63 (2H, s), 5.51 (2H, dd, J = 2.3, 6.8 H), 5.38 (2H, 
dd, J = 1.9, 8.7 Hz), 4.14-4.11 (2H, m), 3.42-3.38 (2H, m), 3.10-3.06 (2H, m), 2.93-2.90 (2H, m), 
2.78 (4H, t, J = 7.0 Hz), 2.72 (6H, s), 2.61-2.54 (4H, m), 2.50 (4H, t, J = 7.3 Hz), 2.15 (6H, s), 2.15-
2.10 (2H, m), 2.06 (4H, t, J = 7.1 Hz), 1.99-1.95 (2H, m), 1.80-1.76 (2H, m), 1.65-1.55 (8H, m), 
1.38 (6H, s), 1.33-1.18 (4H, m), 1.13 (6H, s), 1.08 (6H, d, J = 6.9 Hz), 0.94 (6H, d, J = 6.8 Hz);13C 
NMR (100.6 MHz, CDCl3) δ 216.2 (2C), 172.3 (2C), 170.4 (2C), 164.3 (2C),  152.2 (2C),136.6 
(2C), 120.0 (2C), 116.3 (2C), 78.4 (2C), 76.1 (2C), 73.9 (2C), 57.3 (2C), 53.8 (2C), 52.3 (2C), 43.7 
(2C), 38.5 (2C), 38.0 (2C), 34.5 (2C), 32.6 (2C), 31.8 (2C),  29.4 (2C), 26.3 (2C), 24.4 (2C), 24.1 
(2C), 22.1 (2C), 20.4 (2C), 19.0 (2C), 17.5 (2C), 15.5 (2C), 15.3 (2C); Anal. Calcd. for 
C60H88N2O14S4: C, 60.58; H, 7.46; N, 2.35. Found: C, 60.61; H, 7.48; N, 2.38. [α]D25 = -3.8 (c = 
0.554, CHCl3); HRESI positive MS: Anal. Calcd. for C60H88N2O14S4Na+, 1211.50106; found 
1211.50400.  
 
4 : 1H NMR (400 MHz, CDCl3) δ 6.98 (2H, s), 6.63 (2H, s), 5.51 (2H, dd, J =2.2, 7.1 Hz), 5.38 
(2H, dd, J =1.9, 8.7 Hz), 4.15-4.09 (2H, br. m), 3.41-3.38 (2H, m), 3.10-3.05 (2H, m), 2.93-2.89 
(2H, m), 2.72 (6H, s), 2.58-2.55 (4H, m), 2.40 (6H, br. m), 2.12 (6H, s), 2.11-2.07 (2H, m), 2.01-
1.93 (2H, m), 1.80-1.54 (12H, m), 1.45-1.40 (2H, m), 1.38 (6H, s), 1.32-1.17 (2H, m), 1.13 (6H, s), 
1.07 (6H, d, J = 6.9 Hz), 0.94 (6H, d, J = 6.8 Hz);13C NMR (100.6 MHz, CDCl3) δ  216.4 (2C), 
172.8 (2C), 170.5 (2C), 165.5 (2C), 152.6 (2C), 120.5 (2C), 116.3 (2C), 78.3 (2C), 76.0 (2C), 73.9 
(2C), 71.7 (2C), 57.4 (2C), 53.9 (2C), 52.4 (2C), 43.7 (2C), 38.4 (2C), 34.3 (2C), 33.9 (2C), 31.4 
(2C), 29.6 (2C), 26.2 (2C), 24.9 (2C), 24.1 (2C), 22.2 (2C), 20.5 (2C), 19.1 (2C), 17.6 (2C),  15.7 
(2C), 15.5 (2C); Anal. Calcd. for C58H84N2O14S2: C, 63.48; H, 7.72; N, 2.55. Found: C, 63.51; H, 
7.70; N, 2.51. [α]D25 = -4.3 (c 0.36, CHCl3); HRESI positive MS: Anal. Calcd. for 
C58H84N2O14S2Na+, 1119.52562; found 1119.52719. 
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5 : 1H NMR (400 MHz, CDCl3) δ 6.98 (2H, s), 6.62 (2H, s), 5.50 (2H, dd, J =1.7, 6.9 Hz), 5.37 
(2H, dd, J =1.7, 8.8 Hz), 4.13-4.09 (2H, br. m), 3.39 (2H, dd, J = 6.9, 8.6 Hz), 3.10-3.07 (2H, m), 
2.92-2.89 (2H, m), 2.72 (6H, s), 2.57-2.55 (4H, m), 2.35 (4H, t, J = 7.41 Hz), 2.14 (6H, s), 2.12-
2.08 (2H, m), 1.99-1.92 (2H, m), 1.75-1.53 (14H, m), 1.45-1.39 (6H, m), 1.38 (6H, s), 1.23-1.17 
(2H, m), 1.13 (6H, s), 1.08 (6H, d, J = 6.8 Hz), 0.94 (6H, d, J = 6.8 Hz);13C NMR (100.6 MHz, 
CDCl3) δ 216.2 (2C), 173.0 (2C), 170.4 (2C), 165.5 (2C), 152.3 (2C), 136.6 (2C), 120.1 (2C), 116.3 
(2C), 78.1 (2C), 76.2 (2C), 73.9 (2C), 57.3 (2C), 53.9 (2C), 52.3 (2C), 43.8 (2C), 38.5 (2C), 34.5 
(2C), 34.3 (2C), 31.5 (2C), 29.6 (2C), 28.8 (2C), 26.3 (2C), 24.8 (2C), 24.1 (2C), 22.1 (2C), 20.5 
(2C), 19.0 (2C), 17.5 (2C), 15.5 (2C), 15.4 (2C); Anal. Calcd. for C60H88N2O14S2: C, 64.03; H, 
7.88; N, 2.55. Found: C, 64.06; H, 7.87; N, 2.51.  MS-ESI (MeOH) m/z (%) 1147.8 (100) (MNa)+; 
1126.0 (26) (MH)+; [α]D25 = -6.8 (c = 0.54, CHCl3); HRESI positive MS: Anal. Calcd. for 
C60H88N2O14S2Na+, 1147.55692; found 1147.55527. 
 
6 : 1H NMR (400 MHz, CDCl3) δ 6.99 (2H,s), 6.64 (2H,s), 5.52 (2H, br. d), 5.38 (2H, dd, J =1.7, 
8.8 Hz), 4.14-4.09 (2H, br. m), 3.41-3.37 (2H, m), 3.10-3.06 (2H, m), 2.93-2.92 (2H, m), 2.73 (6H, 
s), 2.58-2.56 (4H, m), 2.35 (4H, t, J = 7.4 Hz), 2.15 (6H, s), 2.10-2.08 (2H, m), 2.00-1.93 (2H, m), 
1.75-1.54 (14H, m), 1.39 (6H, s), 1.36-1.18 (12H, m), 1.14 (6H, s), 1.08 (6H, d, J = 6.9 Hz), 0.95 
(6H, d, J= 6.8 Hz);13C NMR (100.6 MHz, CDCl3) δ 216.2 (2C), 173.1 (2C), 170.4 (2C), 165.3 
(2C), 153.7 (2C), 135.8 (2C), 120.1 (2C), 116.3 (2C), 78.4 (2C), 76.2 (2C), 73.9 (2C), 57.3 (2C), 
53.9 (2C), 52.3 (2C), 43.9 (2C), 38.5 (2C), 34.5 (2C), 34.4 (2C),  31.8 (2C),  29.6 (2C),  29.4 (2C), 
29.1 (2C), 26.3 (2C), 25.0 (2C), 24.6 (2C), 22.2 (2C), 20.5 (2C), 19.0 (2C), 17.5 (2C),  15.5 (2C), 
15.4 (2C); Anal. Calcd. for C62H92N2O14S2: C, 64.56; H, 8.04; N, 2.43. Found: C, 64.56; H, 8.04; N, 
2.43. MS-ESI (MeOH) m/z (%) 1176.7 (100) (MNa)+, 1154.0 (72) (MH)+, [α]D25 = -3.5 (c 0.43, 
CHCl3); HRESI positive MS: Anal. Calcd. for C62H92N2O14S2Na+, 1175.58822; found 1175.58942 
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Tubulin polymerization assay: Tubulin was isolated as pure αβ-tubulin (>95%) from fresh pig 
brain according to the protocol previously reported.6 Tubulin was dissolved in BRB80 buffer (80 
mM PIPES, 1 mM MgCl2, 1 mM EGTA adjusted to pH 6.8 with KOH), Sample was diluted in 
BRB80 buffer to a final volume of 1 mL. Induction of polymerization of purified tubulin was 
determined in a centrifugation-based protein quantification assay. Compounds (5 µM and 10 µM) 
were incubated with tubulin (5 µM) for 30 min at RT. The samples were subsequently centrifuged at 
20000 g for 30 min at 4°C and the protein concentration determined in the supernatant by the 
Bradford method (Biorad, Switzerland). The level of polymer formation upon incubation of 
compounds with purified tubulin was compared to the amount of polymerized tubulin induced with 
25 µM Epo B, which gave maximal polymerization > 95%. The % tubulin polymerization values 
reported in Table 1 thus represent the ratio of polymer formation obtained with test compounds and 
25 µM Epo B, respectively. The % tubulin polymerization was determined in 3 independent 
experiments. 
 
Cell growth assay: A549 and MCF-7 IC50 values for human cancer cell growth inhibition were 
determined for a 72 h exposure period of cells to compounds by quantification of protein content of 
fixed cells by methylene blue staining (Meyer et al., 1989). For further experimental details, see 
Nicolau et al. (2000). The EC50 values given in the text and the IC50 values in the table all represent 
the means of three independent experiments (± standard deviation); HT1080: The 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma Chemical Co., St. Louis, 
MO) dye reduction assay in 96-well microplates was used, as previously described (Rodríguez 
Nieto et al., 2001). 3x103 BAE or 2x103 HT1080 in a total volume of 100 µL of their respective 
growth media were incubated with serial dilutions of the tested compounds. After 3 days of 
incubation (37 oC, 5% CO2 in a humid atmosphere) 10 µl of MTT (5 mg/ml in PBS) were added to 
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each well and the plate was incubated for a further 4 h (37 oC). The resulting formazan was 
dissolved in 150 µL of 0.04 N HCl-2 propanol and read at 550 nm. All determinations were carried 
out in triplicate. IC50 value was calculated as the concentration of compound yielding a 50% of cell 
survival. βD10: Cells were harvested and plated in 96-well flat-bottomed microplates at a density of 
103 cells/well. Assays were performed in quintuplicates. Cells were allowed to attach for 24 h. The 
drugs were prepared in medium at different concentrations and were added to the plates at a volume 
of 100 µl/well. After 24 (or 96) h incubation 20 µl of the CellTiter 96® AQueous One Solution 
Reagent (Promega Corporation, Madison, WI, USA) were added to each well and the plates were 
incubated for one hour at 37 °C. The CellTiter 96® AQueous One Solution Reagent contains a 
tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphe-nyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt; MTS] and an electron coupling reagent (phenazine 
ethosulfate; PES). PES has a high chemical stability, which allows it to form a stable solution with 
MTS. The absorbance was read at 490nm on a plate spectrophotometer (Victor3TM 1420 Multilabel 
Counter, Perkin Elmer Instruments, Shelton, USA). Cell cytotoxicity was expressed as the 
percentage of the controls. 
Endothelial cell differentiation assay: tube formation on Matrigel: Matrigel (50 µL of about 10.5 
mg/mL) at 4 ºC was used to coat each well of a 96-well plate and allowed to polymerize at 37ºC for 
a minimum of 30 min as described previously.12 Some 5x104 BAE cells were added with 200 µL of 
DMEM. Finally, different amounts of the tested compounds were added and incubated at 37 ºC in a 
humidified chamber with 5% CO2. After incubation for 7h, cultures were observed 
(200xmagnification) and photographed with a NIKON inverted microscope DIAPHOT-TMD 
(NIKON Corp., Tokyo, Japan). Each concentration was tested in duplicate, and two different 
observers evaluated the results of tube formation inhibition. 
Endothelial cell migration assay: The migratory activity of BAE cells was assessed using a wound 
migration assay.13 Confluent monolayers in 6-well plates were wounded with pipette tips giving rise 
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to one acellular 1 mm-wide lane per well. After washing, cells were supplied with 1.5 mL complete 
medium in the absence (controls) or presence of the indicated concentrations of the tested 
compounds. Wounded areas were photographed at zero time and after 7, and 24 h of incubation, 
plates were observed under microscope and photos were taken from the same areas as those recorded 
at zero time. 
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